Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report

Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report

Introduction: Tepotinib is a targeted agent for patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). Whereas durvalumab is an immune-checkpoint inhibitor (ICI), which has been administered to those with unresectable stage III...

Full description

Saved in:
Bibliographic Details
Main Authors: Ryota Tatsuhige, Keiki Yokoo, Taku Hatakeyama, Takayuki Nagao, Satoshi Ota, Gen Yamada, Hirofumi Chiba
Format: Article
Language:English
Published: Karger Publishers 2025-01-01
Series:Case Reports in Oncology
Online Access:https://karger.com/article/doi/10.1159/000543251
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items